Dr. Levis on the Challenges of Treating FLT3-ITD AML Targeted Oncology 1:57 10 years ago 739 Скачать Далее
Dr. Levis Discusses the Ideal Use of Quizartinib in FLT3-ITD AML OncLive 1:18 10 years ago 437 Скачать Далее
Dr. Levis on Gilteritinib in Relapsed/Refractory FLT3-Mutated AML OncLive 2:28 4 years ago 1 041 Скачать Далее
Dr. Levis on Quizartinib in AML Patients Without the FLT3-ITD Mutation Targeted Oncology 1:04 11 years ago 371 Скачать Далее
Dr. Levis on the Ideal Way to Use Quizartinib to Treat AML Targeted Oncology 1:28 10 years ago 180 Скачать Далее
BET and FLT3 inhibitor combinations for FLT3-ITD AML VJHemOnc – Video Journal of Hematology & HemOnc 2:43 3 years ago 179 Скачать Далее
The challenges of using kinase inhibitors for AML treatment VJHemOnc – Video Journal of Hematology & HemOnc 1:36 6 years ago 64 Скачать Далее
Best treatment strategy for FLT3 ITD AML VJHemOnc – Video Journal of Hematology & HemOnc 2:20 6 years ago 1 177 Скачать Далее
LBA: gilteritinib as post-transplant maintenance therapy in FLT3-ITD AML VJHemOnc – Video Journal of Hematology & HemOnc 1:43 1 year ago 166 Скачать Далее
Mark Levis, MD, on why the FLT3 target is important in AML OBRoncology 1:50 8 years ago 514 Скачать Далее
Dr. Levis on the Background and Future of Quizartinib for AML Targeted Oncology 1:37 10 years ago 129 Скачать Далее
Randomised trial of the FLT3 inhibitor gilteritinib as post-transplant maintenance for FLT3-ITD AML ecancer 2:34 11 months ago 55 Скачать Далее
Dr. Levis on a Phase II Trial Examining Quizartinib in AML Targeted Oncology 3:00 11 years ago 226 Скачать Далее
Myelosuppression related to gilteritinib treatment in AML & impact on clinical trial design VJHemOnc – Video Journal of Hematology & HemOnc 0:57 1 year ago 253 Скачать Далее
Impact of MRD on FLT3-ITD AML VJHemOnc – Video Journal of Hematology & HemOnc 2:54 5 years ago 264 Скачать Далее
The prognostic value of FLT3-ITD residual disease in AML VJHemOnc – Video Journal of Hematology & HemOnc 1:49 1 year ago 213 Скачать Далее
